Recursion Pharmaceuticals is trading 4.79% higher at $4.26 on October 2, 2026, with broader market strength likely contributing to the gain.
- Major indices are sharply higher after weak September jobs data eased rate-hike concerns.
- An October 2 report discusses a two-year Tempus AI license and a $12 million non-refundable fee, but does not link the deal to the move.
- No clear company-specific catalyst or trading-volume details were available.